Research - We’ve considered Medivation (MDVN) a long-term play on the clinical and commercial strength of XTANDI (enzalutamide), which with the aid of Astellas (ALPMY) is well on its way toward … Continue Reading
PremiumResearch - A risk-mitigating strategy for being involved in Alcobra’s (ADHD) upcoming phase 3 results in ADHD.
PremiumInsights - Ebola stocks are still in vogue, though for new reasons on Thursday. The DailyMail reported on Wednesday evening that up to four drug companies, including Shire … Continue Reading
Read nowResearch - InterMune’s (ITMN) stock rose 14 percent last Wednesday, closing at a 14-year high of $52.06, on rumors that big pharma is lining up to bid for … Continue Reading
Read nowInsights - Arrowhead Research (ARWR) raised as many questions as it answered this week when the company reported interim results from a mid-stage study of hepatitis B drug … Continue Reading
Read nowResearch - OWN PCYC as Imbruvica continues to secure foothold in oncology. Cash and emerging pipeline offer options diversification for this small company. Second quarter results demonstrate continued growth … Continue Reading
PremiumResearch - Amicus Therapeutics (FOLD), with a current market value of just $271 million, represents a high-risk, high reward play for investors willing to bet that the … Continue Reading
Premium
